Search

Displaying results 4751 - 4760 of 10000 in total
  1. Drug

    GTI 2040

    go.drugbank.com/drugs/DB05801
    Investigational

    GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

  2. Drug

    Besigomsin

    go.drugbank.com/drugs/DB20894
    Experimental

    Besigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.

    Synonyms: Gomisin a, (+)-gomisin aCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  4. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

  5. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  6. Drug

    Hydrolyzed soy protein

    go.drugbank.com/drugs/DB15607
    Investigational

    Mixtures: P3 Ai, P3 Ai
  7. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  8. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

  9. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation … , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease.

  10. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.